

2017 No. 634

DANGEROUS DRUGS

The Misuse of Drugs Act 1971 (Amendment) Order 2017

Made - - - - *3rd May 2017*

Coming into force in accordance with article 1

At the Court at Buckingham Palace, the 3rd day of May 2017

Present,

The Queen's Most Excellent Majesty in Council

In accordance with section 2(5) of the Misuse of Drugs Act 1971(a) a draft of this Order has been laid before Parliament on the recommendation of the Advisory Council on the Misuse of Drugs and approved by a resolution of each House of Parliament.

Accordingly, Her Majesty, in exercise of the powers conferred upon Her by section 2(2) of that Act, is pleased, by and with the advice of Her Privy Council, to order as follows:

Citation and commencement

1. This Order may be cited as the Misuse of Drugs Act 1971 (Amendment) Order 2017 and comes into force on the twenty-eighth day after the day on which it is made.

Amendments to the Misuse of Drugs Act 1971

2. The following amendments are made to Schedule 2 to the Misuse of Drugs Act 1971.

3. In paragraph 1(a) of Part 1 (which specifies the drugs which are subject to control under that Act as Class A drugs), after "3,4-dichloro-*N*-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (AH-7921)." insert—

"3,4-dichloro-*N*-[2-(dimethylamino)cyclohexyl]-*N*-methylbenzamide (U-47,700)."

4. In paragraph 1(a) of Part 2 (which specifies the drugs which are subject to control under that Act as Class B drugs)—

(a) after "Amphetamine." insert—

"*N*-Benzyl-ethylphenidate.";

(b) after "Ethylmorphine (3-ethylmorphine)." insert—

(a) 1971 c. 38. Schedule 2 has been amended by section 21 of the Drugs Act 2005 (c. 17) and S.I. 1973/771, 1975/421, 1977/1243, 1979/299, 1983/765, 1984/859, 1985/1995, 1986/2230, 1989/1340, 1990/2589, 1995/1966, 1996/1300, 1998/750, 2001/3932, 2003/1243, 2003/3201, 2005/3178, 2006/3331, 2008/3130, 2009/3209, 2010/1207, 2010/1833, 2011/744, 2012/1390, 2013/239, 2014/1106, 2014/1352, 2014/3271, 2015/215 and 2016/1109.

“Ethlynaphthidate.

Ethylphenidate.”;

(c) after “Glutethimide.” insert—

“Isopropylphenidate (IPP or IPPD).”;

(d) after “Methcathinone.” insert—

“Methylmorphenate.”

“Methlynaphthidate (HDMP-28).”;

(e) after “Propiram.” insert—

“Propylphenidate.”;

(f) after “Zipeprol.” insert—

“3,4-Dichloroethylphenidate.”

“3,4-Dichloromethylphenidate (3,4-DCMP).”;

(g) after “2-((Dimethylamino)methyl)-1-(3-hydroxyphenyl)cyclohexanol” insert—

“4-Fluoroethylphenidate.”

“4-Fluoromethylphenidate.”

“4-Methylmethylphenidate.”.

5. In paragraph 1(a) of Part 3 (which specifies the drugs which are subject to control under that Act as Class C drugs)—

(a) before “Alprazolam” insert—

“Adinazolam (1-(8-Chloro-6-phenyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepin-1-yl)-*N,N*-dimethylmethanamine).”;

(b) after “Bromazepam” insert—

“Bromazolam (8-bromo-1-methyl-6-phenyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine).”;

(c) after “Cathinone” insert—

“4'-Chlorodiazepam (7-Chloro-5-(4-chlorophenyl)-1-methyl-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one).”;

(d) after “Clonazepam” insert—

“Clonazolam (6-(2-Chlorophenyl)-1-methyl-8-nitro-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine).”;

(e) after “Delorazepam” insert—

“Deschloroetizolam (2-Ethyl-9-methyl-4-phenyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine).”;

(f) after “Diazepam” insert—

“Diclazepam (7-Chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one).”;

(g) after “Ethyl loflazepate” insert—

“Etizolam.”;

(h) after “Fenproporex” insert—

“Flubromazepam (7-Bromo-5-(2-fluorophenyl)-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one).

Flubromazolam (8-Bromo-6-(2-fluorophenyl)-1-methyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine).”;

(i) after “Flurazepam” insert—

“Fonazepam (5-(2-Fluorophenyl)-7-nitro-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one).”;

(j) after “4-Hydroxy-*n*-butyric acid” insert—

“3-Hydroxyphenazepam (7-Bromo-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one).”;

(k) after “Mazindol” insert—

“Meclonazepam (5-(2-Chlorophenyl)-3-methyl-7-nitro-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one).”;

(l) after “Methyprylone” insert—

“Metizolam (4-(2-Chlorophenyl)-2-ethyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepine).”;

(m) after “Midazolam” insert—

“Nifoxipam (5-(2-Fluorophenyl)-3-hydroxy-7-nitro-1,3-dihydro-2*H*-1,4-benzodiazepin-2-one).”;

(n) after “Nitrazepam” insert—

“Nitrazolam (1-Methyl-8-nitro-6-phenyl-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine).”;

(o) after “Prazepam” insert—

“Pyrazolam (8-Bromo-1-methyl-6-(2-pyridinyl)-4*H*-[1,2,4]triazolo[4,3-*a*][1,4]benzodiazepine).”.

Richard Tilbrook
Clerk of the Privy Council

EXPLANATORY NOTE

(This note is not part of the Order)

This Order brings certain drugs under the control of the Misuse of Drugs Act 1971 (‘the Act’). Article 3 of this Order brings a synthetic opioid known as U-47,700 under permanent control as a Class A drug under the Act. Article 4 brings several methylphenidate related materials under permanent control as Class B drugs. A number of these methylphenidate related materials were specified under section 2A of the Act as drugs subject to temporary control by virtue of the Misuse of Drugs Act 1971 (Temporary Class Drug) Order 2016 (S.I. 2016/650) and cease to be subject to such temporary control on the coming into force of this Order in accordance with section 2A(6)(b) of the Act. Article 5 brings several designer benzodiazepines under permanent control as Class C drugs.